Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor versus ticagrelor in STEMI patients undergoing primary PCI
2016-000195-19Phase 4Completed
- Sponsor
- The Royal Wolverhampton NHS Trust
- Start
- Feb 2016
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cangrelor and ticagrelor in myocardial infarction (MI) (2 arms), sponsored by The Royal Wolverhampton NHS Trust. Primary endpoint: Assessment of the two drug therapies by platelet-related and myocardial injury measures. Started Feb 2016; status: completed.
02
Drugs
cangrelorticagrelor
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2016-000195-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000195-19.